Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
44.24
USD
|
+0.89%
|
|
+4.41%
|
-7.49%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,467
|
9,158
|
5,732
|
3,248
|
3,926
|
3,678
|
-
|
-
|
Enterprise Value (EV)
1 |
1,712
|
7,956
|
4,992
|
2,500
|
3,149
|
3,343
|
3,379
|
3,678
|
P/E ratio
|
-6
x
|
-45.1
x
|
-12.6
x
|
-4.58
x
|
-5.8
x
|
-6.84
x
|
-8.46
x
|
-13.3
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
23.8
x
|
33.8
x
|
16.3
x
|
8.94
x
|
9.04
x
|
7.15
x
|
5.84
x
|
4.22
x
|
EV / Revenue
|
16.5
x
|
29.4
x
|
14.2
x
|
6.88
x
|
7.25
x
|
6.5
x
|
5.37
x
|
4.22
x
|
EV / EBITDA
|
-4.12
x
|
-25
x
|
-13.5
x
|
-3.96
x
|
-5.8
x
|
-6.63
x
|
-8.57
x
|
-28.7
x
|
EV / FCF
|
-4.62
x
|
-45.2
x
|
-12.1
x
|
-5.03
x
|
-6.07
x
|
-8.12
x
|
-8.81
x
|
-10.7
x
|
FCF Yield
|
-21.6%
|
-2.21%
|
-8.25%
|
-19.9%
|
-16.5%
|
-12.3%
|
-11.4%
|
-9.33%
|
Price to Book
|
3.78
x
|
7.3
x
|
6.32
x
|
9.23
x
|
12.8
x
|
4.95
x
|
4.42
x
|
4.58
x
|
Nbr of stocks (in thousands)
|
57,771
|
66,156
|
68,162
|
70,106
|
82,106
|
83,133
|
-
|
-
|
Reference price
2 |
42.71
|
138.4
|
84.09
|
46.33
|
47.82
|
44.24
|
44.24
|
44.24
|
Announcement Date
|
2/13/20
|
2/11/21
|
2/10/22
|
2/16/23
|
2/15/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
103.7
|
271
|
351.4
|
363.3
|
434.2
|
514.7
|
629.8
|
871.8
|
EBITDA
1 |
-415.6
|
-317.9
|
-368.5
|
-630.7
|
-543.2
|
-504.2
|
-394.4
|
-128.3
|
EBIT
1 |
-424.2
|
-330.1
|
-381.7
|
-648.9
|
-569.2
|
-496.6
|
-434.1
|
-268.3
|
Operating Margin
|
-408.98%
|
-121.8%
|
-108.63%
|
-178.6%
|
-131.08%
|
-96.48%
|
-68.93%
|
-30.77%
|
Earnings before Tax (EBT)
1 |
-399.4
|
-185.4
|
-453
|
-701.7
|
-608.5
|
-534.3
|
-464.2
|
-300.6
|
Net income
1 |
-402.7
|
-186.6
|
-454
|
-707.4
|
-606.6
|
-531.9
|
-459.5
|
-314.8
|
Net margin
|
-388.31%
|
-68.84%
|
-129.2%
|
-194.71%
|
-139.7%
|
-103.34%
|
-72.97%
|
-36.11%
|
EPS
2 |
-7.120
|
-3.070
|
-6.700
|
-10.12
|
-8.250
|
-6.466
|
-5.230
|
-3.323
|
Free Cash Flow
1 |
-370.2
|
-176.1
|
-411.8
|
-496.6
|
-519.1
|
-411.7
|
-383.7
|
-343
|
FCF margin
|
-356.96%
|
-64.98%
|
-117.18%
|
-136.68%
|
-119.53%
|
-79.99%
|
-60.92%
|
-39.35%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/13/20
|
2/11/21
|
2/10/22
|
2/16/23
|
2/15/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
81.65
|
83.39
|
79.94
|
89.34
|
90.7
|
103.3
|
100.5
|
108.3
|
98.05
|
127.4
|
116.8
|
125.9
|
129.8
|
142.9
|
129.4
|
EBITDA
|
-86.61
|
-99.03
|
-
|
-137.1
|
-220.4
|
-140.7
|
-148.9
|
-142.6
|
-137.9
|
-113.8
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-89.83
|
-102.6
|
-136.6
|
-141.6
|
-225.1
|
-145.6
|
-154.1
|
-148
|
-145.1
|
-122
|
-133.3
|
-125.2
|
-123.2
|
-118.7
|
-125.7
|
Operating Margin
|
-110.02%
|
-122.99%
|
-170.93%
|
-158.48%
|
-248.14%
|
-140.91%
|
-153.34%
|
-136.61%
|
-147.98%
|
-95.81%
|
-114.11%
|
-99.48%
|
-94.94%
|
-83.02%
|
-97.18%
|
Earnings before Tax (EBT)
1 |
-72.82
|
-122.4
|
-151.8
|
-157.9
|
-238.8
|
-153.3
|
-163.5
|
-159.1
|
-159
|
-126.9
|
-138.3
|
-131.2
|
-127.8
|
-119.7
|
-132.4
|
Net income
1 |
-73
|
-122.5
|
-152.3
|
-158.2
|
-245.1
|
-151.8
|
-164
|
-159.8
|
-159.6
|
-123.2
|
-139.7
|
-131.4
|
-128.6
|
-124
|
-132.1
|
Net margin
|
-89.41%
|
-146.85%
|
-190.55%
|
-177.03%
|
-270.23%
|
-146.91%
|
-163.16%
|
-147.57%
|
-162.82%
|
-96.7%
|
-119.58%
|
-104.37%
|
-99.05%
|
-86.76%
|
-102.11%
|
EPS
2 |
-1.080
|
-1.790
|
-2.190
|
-2.260
|
-3.500
|
-2.160
|
-2.330
|
-2.250
|
-2.230
|
-1.520
|
-1.752
|
-1.642
|
-1.586
|
-1.519
|
-1.540
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/2/21
|
2/10/22
|
5/5/22
|
7/28/22
|
11/2/22
|
2/16/23
|
5/4/23
|
8/3/23
|
11/2/23
|
2/15/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
755
|
1,202
|
740
|
748
|
777
|
334
|
298
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-370
|
-176
|
-412
|
-497
|
-519
|
-412
|
-384
|
-343
|
ROE (net income / shareholders' equity)
|
-63.8%
|
-20.6%
|
-43.7%
|
-111%
|
-193%
|
-110%
|
-66.7%
|
-39.8%
|
ROA (Net income/ Total Assets)
|
-43.4%
|
-12.9%
|
-27.7%
|
-46.1%
|
-40%
|
-39.2%
|
-35.4%
|
-31.2%
|
Assets
1 |
927.5
|
1,447
|
1,641
|
1,534
|
1,518
|
1,357
|
1,300
|
1,007
|
Book Value Per Share
2 |
11.30
|
19.00
|
13.30
|
5.020
|
3.740
|
8.940
|
10.00
|
9.660
|
Cash Flow per Share
2 |
-6.100
|
-2.170
|
-4.940
|
-5.440
|
-6.460
|
-5.460
|
-4.140
|
-
|
Capex
1 |
24.8
|
43.9
|
73.1
|
116
|
44.3
|
46.7
|
44.3
|
43.8
|
Capex / Sales
|
23.94%
|
16.2%
|
20.8%
|
31.96%
|
10.19%
|
9.07%
|
7.04%
|
5.02%
|
Announcement Date
|
2/13/20
|
2/11/21
|
2/10/22
|
2/16/23
|
2/15/24
|
-
|
-
|
-
|
Last Close Price
44.24
USD Average target price
89.52
USD Spread / Average Target +102.36% Consensus |
1st Jan change
|
Capi.
|
---|
| -7.49% | 3.68B | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.73B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|